Entities / Company
Verona Pharma.
company in London, United Kingdom
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Gone quiet
No new reports in 90+ days-
AstraZeneca gained global rights to TQC3721 outside China, while Merck acquired the developer of Ohtuvayre, a drug challenging in COPD treatment.Some support1 report
-
Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.Some support1 report
-
Merck acquired Verona Pharma for $10 billion on August 5, 2025.Well supported11 reports
-
Verona Pharma researches drugs primarily in the United Kingdom.Speculative1 report
-
Analyst raised the price target for Verona Pharma to $160.Speculative1 report
-
Merck announced the acquisition of Verona Pharma plc, a development discussed by Jim Cramer in the context of AI stock benefits from tariffs.Some support2 reports
-
Vipshop, Futu Holdings, Verona Pharma, and GDS were included in a curated low-beta portfolio on July 30, 2025.Some support1 report
-
Verona Pharma provided funding support for a study on July 31, 2025.Some support1 report
-
Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction.Some support2 reports1 development inside
No events began in the chosen period. Widen it, or reset.
Around Verona Pharma this week
News at the entities that move Verona Pharma most-
Merck StructuralModerna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Moves Verona Pharma
-
Jim Cramer Mentioned togetherFed rate hikes trigger market sell-offs, prompting Jim Cramer to advise selling while Elon Musk enters the telecom sector.Moves Verona Pharma
-
MSD Mentioned togetherBioinvent combined its antibody with MSD's anti-PD-1 therapy.Moves Verona Pharma
Connections
The 3 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck Structural
Merck acquired Verona Pharma for $10 billion, integrating its pipeline and products into Merck's operations.
-
Jim Cramer Mentioned together
Jim Cramer publicly discusses Verona Pharma, referencing its stock status and acquisition news.
-
MSD Mentioned together
No evidence was provided regarding the relationship between Verona Pharma and MSD.
History
Events by the month they beganJuly 2026
1 eventJune 2026
8 events- Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.
- Merck acquired Verona Pharma for $10 billion on August 5, 2025.
- Verona Pharma researches drugs primarily in the United Kingdom.
- Analyst raised the price target for Verona Pharma to $160.
- Merck announced the acquisition of Verona Pharma plc, a development discussed by Jim Cramer in the context of AI stock benefits from tariffs.
- Vipshop, Futu Holdings, Verona Pharma, and GDS were included in a curated low-beta portfolio on July 30, 2025.
- Verona Pharma provided funding support for a study on July 31, 2025.
- Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction.